Lillie D. Shockney RN, BS, MAS, HON-ONN-CG
University Distinguished Service Professor of Breast Cancer, Professor of Surgery, Johns Hopkins University School of Medicine; Co-Founder, Academy of Oncology Nurse & Patient Navigators; Co-Developer, Work Stride — Managing Cancer at Work, Johns Hopkins Healthcare Solutions, Baltimore, MarylandProf. Lillie D. Shockney, a specialist in the care of patients with breast cancer, is well-known in the cancer field, especially the areas of navigation, survivorship, patient-centered care, preservation of quality of life, end-of-life planning and care, improving the cancer patient’s experience, and clinical outcomes. Her research focuses on the preservation of quality of life for patients with metastatic breast cancer.
In 2016, Prof. Shockney was promoted to full professor, and she is the only nurse at Johns Hopkins to have a primary faculty appointment in the School of Medicine and the only nurse in the country to have reached the highest academic faculty ranking and be appointed to a faculty chair as a University Distinguished Service Professor of Breast Cancer at Johns Hopkins University School of Medicine.
Prof. Shockney is the co-founder of the Academy of Oncology Nurse & Patient Navigators (AONN+), a national professional organization for those working in the navigation space with oncology patients, which has more than 9000 members. She has served as a consultant for breast cancer for ABC News and Good Morning America and has been consulted regularly by the Today Show and CNN. She currently serves on 28 medical advisory boards. She has authored 30 books and more than 350 articles on breast cancer and on topics such as oncology navigation, survivorship, and patient advocacy. She has received 62 awards — 54 national awards, 7 state awards, and 1 international award, and several national lifetime achievement awards.
Disclosures
- Speakers bureau for Pfizer Oncology
Recent Contributions to PracticeUpdate:
- Survival Analysis in Patients With Brain Metastases at Initial Breast Cancer Diagnosis Over the Last Decade
- Development and Methodological Validation of a Modified Staging System for De Novo Metastatic Breast Cancer
- Patient Advocate–Led Survey Results Regarding MBC Treatment Side Effects and Impact on Quality of Life
- Impact of Initial Tumor Response on Survival Outcomes in Patients With HER2+ Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab
- Weight, Cardiometabolic, and Hormonal Outcomes of Whole-Food, Plant-Based Diet in Patients With Metastatic Breast Cancer
- Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Patients With Advanced Breast Cancer
- Brain Metastases in the Setting of Stable vs Progressing Extracranial Disease Among Patients With Metastatic Breast Cancer
- Real-World Treatment Patterns and Survival Outcomes in Patients With De Novo HER2+ Metastatic Breast Cancer Prior to and After 2013
- Patterns and Outcomes of CNS Metastases in Patients With Breast Cancer With Germline BRCA Pathogenic Variants vs Non-Carriers
- Impact of Allosteric PI3Kα Inhibition on On-Target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations